Attempts to Optimize Active Specific Immunotherapy for Melanoma

References

• Kan-Mitchell J., Mitchell M. S. Human monoclonal antibodies for the diagnosis of tumors. In Vitro Diagnosis of Human Tumors Using Monoclonal Antibodies, H. Z. Kupchik. Marcel Dekker, New York 1988; 289–304
   Google Scholar
• Ribi E., Cantrell J. L., Takayama K., Qureshi N., Peterson J., Ribi H. O. Lipid A and immunotherapy. Rev. Infect. Dis 1984; 6: 567–572
   PubMedGoogle Scholar
• Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H., Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988; 48: 5883–5893
   PubMed Web of Science ®Google Scholar
• Mitchell M. S., Harel W., Kempf R. A., Hu E., Kan-Mitchell J., Boswell W. D., Dean G., Stevenson L. Active specific immunotherapy for melanoma. J. Clin. Oncol. 1990; 8: 856–869
   PubMed Web of Science ®Google Scholar
• Edelson R. Light-activated drugs. Scientific American Aug, 1988; 68–75
   PubMedGoogle Scholar
• Perez M., Gapas Y., O'Neil D., Edelson R., Berger C. Inhibition of murine autoimmune disease by reinfusion of syngeneic lymphocytes inactivated with psoralen and UVA light. Clin. Res. 1986; 34: 774A, (abstract)
   Google Scholar
• Vose B. M. Quantitation of proliferative and cytotoxic precursor cells directed against human tumors: Limiting dilution analysis in peripheral blood and at the tumor site. Int. J. Cancer 1982; 30: 135–142
   PubMedGoogle Scholar
• Oh S. K., Cerda S., Kim S. H., Walker J., Harel W., Mitchell M. S. Cyclophosphamide potentiates immune response via down-modulating the immunosuppressive acute phase protein synthesis of liver in tumor bearing patients. Proc. Am. Assoc. Cancer Res. 1990; 31: 235, (abstract)
   Google Scholar
• Berd D., Maguire H. C., Jr., Mastrangelo M. J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 1984; 44: 5439–5443
   PubMed Web of Science ®Google Scholar
• Vbsika G., Schmidtke J., Goldman A., Parker R., Ribi E., Gray G. R. Phase II study of intralesional immunotherapy with oil-attached mycobacterium smegmatis cell wall skeleton and trehalose dimycolate. Cancer Immunol. Immunother. 1979; 6: 135–142
   Google Scholar
• Vbsika G., Giddings C., Gray G. R. Phase I study of intravenous mycobacterial cell wall skeleton and trehalose dimycolate attached to oil droplets. J. Biol. Resp. Modif. 1984; 3: 620–626
   PubMedGoogle Scholar
• Vosika G. J., Schmidtke J., Goldman A., Ribi E., Parker R., Gray G. R. Local and systemic immunotherapy of human cancer with mycobacterial cell wall skeleton and trehalose dimycolate (P3). Augmenting Agents in Cancer Therapy, E. M. Hersh, J. A. Chirigos, M. J. Mastrangelo. Raven, New York 1981; 33–51
   Google Scholar
• Darrow T. L., Slingluff C. L., Jr., Seigler H. F. The role of HLA Class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J. Immunol. 1989; 142: 3329–3335
   PubMed Web of Science ®Google Scholar
• Wolfel X., Klehmann E., Muller C., Schutt K. -H., Meyer Zum Buschenfelde K. -H., Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 1989; 170: 787–810
   Google Scholar
• Berd D., Mastrangelo M. J. Active immunotherapy of human melanoma exploiting the immunopoten-tiating effects of cyclophosphamide. Cancer Investigation 1988; 6: 337–349
   PubMed Web of Science ®Google Scholar
• Zinkernagel R. M., Doherty P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701–702
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Cellular Immunity and the Immunotherapy of Cancer, M. T. Lotzeand, O. J. Finn. Wiley-Liss, New York 1990; 383–393
   Google Scholar
• Nikaein A., Boyer B., McQueen K., Ryan D. H. Development of Class-I-specific helper-inducer T-cell clone. Human Immunol. 1987; 19: 205–214
   PubMedGoogle Scholar
• Vanky F., Stuber G., Rotstein S., Klein E. Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative. Cancer Immunol. Immunother. 1989; 28: 17–21
   PubMedGoogle Scholar
• Hutchins J. T., Deans R. J., Uchiwara C., Mitchell M. S., Kan-Mitchell J. Novel gene sequences expressed by human melanoma cells identified by molecular subtraction. Cancer Res. 1991; 51: 1418–1425
   PubMed Web of Science ®Google Scholar
• Giovarelli M., Santoni A., Forni G. Alloantigen-activated lymphocytes from mice bearing a spontaneous “nonimmunogenic” adenocarcinoma inhibit its growth in vivo by recruiting host immuno-reactivity. J. Immunol. 1985; 133: 3596–3603
   Google Scholar
• Forni G., Fujiwara H., Martino F., Hamaoka T., Jemma C., Caretto P., GioVarelli M. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Revs. 1988; 7: 289–309
   PubMedGoogle Scholar
• Hersey P. Vaccinia viral lysates in treatment of melanoma. Biomodulation: A New Approach to Cancer Treatment, M. S. Mitchell. Pergamon, Oxford 1991, (in press)
   Google Scholar